The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

S&P 500 futures steady after record highs. Novo Nordisk and Twilio surge, while Boeing posts $4B loss. Traders eye Fed policy ...

Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...

In addition to an earnings beat, American Express disclosed a 17% increase to its quarterly dividend. Here's what that means ...

The pound was quoted at USD1.2479 late Monday afternoon in London, down from USD1.2490 at the equities close on Friday. The euro stood lower at USD1.0505, against USD1.0510. Against the yen, the ...

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

Current analysis indicates the stock is trading near its Fair Value, with analyst targets ranging from $80.37 to $160.02. In other recent news, Novo Nordisk, a pharmaceutical company, has been ...